Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTT106 for Erectile Dysfunction Associated with Benign Prostatic Hyperplasia
NCT06264414Phase 3Not yet recruiting
- Sponsor
- EMS
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DTT-106 in erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) (2 arms), sponsored by EMS. Primary endpoint: International Index of Erectile Function - Erectile Function Domain at 12 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
DTT-106
03
Conditions
erectile dysfunction (ED)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06264414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264414.